Skip to Content
Morningstar

Abbott Laboratories ABT

Morningstar Rating
Unlock
Stock XNYS Rating as of
$105.24 −0.72 (0.68%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Abbott Earnings: Broad-Based Strength Across Portfolio Leaves Abbott on Track to Hit 2024 Estimates

Debbie S. Wang

Abbott Labs delivered strong second-quarter results that were generally consistent with our expectations and, with the firm on track to meet our full-year projections, we're leaving our fair value estimate unchanged. Despite foreign exchange headwinds, Abbott continues to show strength, reflecting resumption of growth in key businesses, as well as new products in others. We saw little in the quarter to suggest Abbott's narrow economic moat has shifted one way or the other.

Read Full Report

Price vs Fair Value

View History
ABT is trading at a 242% premium.
Price
$105.24
Fair Value
$691.00
Uncertainty
Medium
1-Star Price
$482.40
5-Star Price
$57.40
Economic Moat
Gggxwgj
Capital Allocation
Lpyhrgvl

Bulls Say, Bears Say

Bulls

Abbott has been investing in structural heart products and recently entered the left atrial appendage closure market.

Bears

Clinical data on drug-eluting stents and alternative therapies have put a crimp in percutaneous coronary procedures, as medical therapy and coronary bypass have gained favor.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABT is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$105.96
Day Range
$104.66–107.14
52-Week Range
$89.67–121.64
Bid/Ask
$99.90 / $100.50
Market Cap
$183.08 Bil
Volume/Avg
8.6 Mil / 6.1 Mil

Key Statistics

Price/Earnings (Normalized)
23.97
Price/Sales
4.52
Dividend Yield (Trailing)
2.05%
Dividend Yield (Forward)
2.09%
Total Yield
2.55%

Company Profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Core
Total Number of Employees
114,000
Website
https://www.abbottinvestor.com

Competitors

Valuation

View More
Metric
ABT
BSX
MDT
Price/Earnings (Normalized)
 23.9735.0115.11
Price/Book Value
 4.725.532.06
Price/Sales
 4.527.283.23
Price/Cash Flow
 18.4131.8314.40
Price/Earnings
ABT
BSX
MDT

Financial Strength

Metric
ABT
BSX
MDT
Quick Ratio
 1.110.941.31
Current Ratio
 1.601.662.03
Interest Coverage
 10.888.887.73
Quick Ratio
ABT
BSX
MDT

Profitability

Metric
ABT
BSX
MDT
Return on Assets (Normalized)
 10.57%9.16%7.64%
Return on Equity (Normalized)
 20.40%16.77%13.51%
Return on Invested Capital (Normalized)
 14.72%11.67%9.78%
Return on Assets
ABT
BSX
MDT
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Stryker Corp
SYK
LvjssqjxbtTrrv$126.3 Bil
 Boston Scientific Corp
BSX
VjyqspfFzxjc$110.1 Bil
 Medtronic PLC
MDT
KqlygxprNvqhkp$100.9 Bil
 Edwards Lifesciences Corp
EW
YdkkfwkmnYfnmhl$37.6 Bil
 DexCom Inc
DXCM
JrztzqljxkJdch$25.6 Bil
 Koninklijke Philips NV ADR
PHG
TbvkmwpZvvqtk$24.1 Bil
 Steris PLC
STE
ZthjbbnzgKbkjmj$23.0 Bil
 Zimmer Biomet Holdings Inc
ZBH
McblgnjbRjcj$22.9 Bil
 Align Technology Inc
ALGN
ShjzqlhbJvzkw$16.6 Bil

Sponsor Center